{"protocolSection": {"identificationModule": {"nctId": "NCT00292162", "orgStudyIdInfo": {"id": "05/S0704/47"}, "organization": {"fullName": "NHS Greater Glasgow and Clyde", "class": "OTHER"}, "briefTitle": "Curing Atrial Fibrillation in Heart Failure", "officialTitle": "Radiofrequency Ablation for Atrial Fibrillation in Advanced Chronic Heart Failure"}, "statusModule": {"statusVerifiedDate": "2012-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-01"}, "primaryCompletionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-02-14", "studyFirstSubmitQcDate": "2006-02-14", "studyFirstPostDateStruct": {"date": "2006-02-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-08-01", "resultsFirstSubmitQcDate": "2012-05-29", "resultsFirstPostDateStruct": {"date": "2012-06-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-05-29", "lastUpdatePostDateStruct": {"date": "2012-06-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Michael MacDonald", "investigatorTitle": "Cardiology ST6", "investigatorAffiliation": "NHS Greater Glasgow and Clyde"}, "leadSponsor": {"name": "NHS Greater Glasgow and Clyde", "class": "OTHER"}}, "descriptionModule": {"briefSummary": "Heart failure is a condition that occurs when the heart muscle weakens and no longer contracts normally. Half of these patients have an irregularity of heart rhythm called atrial fibrillation (AF). Patients with both heart failure and AF spend more time in hospital, and die earlier than those with heart failure alone. AF is difficult to treat with conventional methods in patients with heart failure. Radiofrequency ablation is a new technique used to cure AF. The investigators aim to establish if radiofrequency ablation for atrial fibrillation in patients with advanced heart failure can result in marked improvement in the function of the heart."}, "conditionsModule": {"conditions": ["Chronic Heart Failure", "Atrial Fibrillation"], "keywords": ["Chronic Heart Failure", "Atrial Fibrillation", "Radiofrequency Ablation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 41, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "medical therapy", "type": "ACTIVE_COMPARATOR", "description": "Standard therapy for heart failure with angiotensin converting enzyme inhibitors(ACE) - (Ramipril, enalapril, lisinopril, captopril, perindopril), beta-blocker (BB) - (carvedilol, bisoprolol, metoprolol), Aldosterone antagonists (spironolactone) +/- diuretics and digoxin", "interventionNames": ["Drug: ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril", "Drug: Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol", "Drug: Aldosterone Antagonists - spironolactone"]}, {"label": "Radiofrequency ablation (RFA)", "type": "ACTIVE_COMPARATOR", "description": "Isolation of the pulmonary veins using radiofrequency ablation", "interventionNames": ["Procedure: radiofrequency ablation"]}], "interventions": [{"type": "PROCEDURE", "name": "radiofrequency ablation", "description": "isolation of the pulmonary veins with radiofrequency ablation (RFA)", "armGroupLabels": ["Radiofrequency ablation (RFA)"], "otherNames": ["radiofrequency ablation (RFA)", "pulmonary vein isolation (PVI)"]}, {"type": "DRUG", "name": "ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril", "description": "Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.", "armGroupLabels": ["medical therapy"]}, {"type": "DRUG", "name": "Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol", "description": "Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.", "armGroupLabels": ["medical therapy"]}, {"type": "DRUG", "name": "Aldosterone Antagonists - spironolactone", "description": "Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.", "armGroupLabels": ["medical therapy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%", "description": "left ventricular ejection fraction (LVEF) is a measure of the % of blood ejected from the ventricle in one heart beat. It is a measure of cardiac function. We measured LVEF at baseline and at 6 months, to assess whether there had been a change in the patients cardiac function over time.", "timeFrame": "baseline and 6 months"}, {"measure": "Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)", "description": "Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)in %", "timeFrame": "Baseline"}, {"measure": "Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months", "description": "Left Ventricular Ejection Fraction as measured by Magnetic Resonance Imaging (MRI)at 6 months", "timeFrame": "6 months"}], "secondaryOutcomes": [{"measure": "Plasma B-type Natriuretic Peptide (BNP)", "description": "venous blood taken to assess levels of the above peptide. High evels of the peptide are associated with adverse prognosis. Blood levels are taken at baseline and 6 months. The change over 6 months is assessed, thereore it is possible to have a negative number if the level falls.", "timeFrame": "baseline and 6 months"}, {"measure": "Plasma B-type Natriuretic Peptide (BNP) at Baseline", "description": "Plasma B-type Natriuretic Peptide (BNP) measured at basline", "timeFrame": "Baseline"}, {"measure": "Plasma B-type Natriuretic Peptide (BNP) at 6 Months", "description": "Plasma B-type Natriuretic Peptide (BNP)", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Informed consent\n* Persistent atrial fibrillation (AF)\n* New York Heart Association (NYHA) II, III and IV chronic heart failure (CHF) despite optimal medical therapy for at least 3 months\n* left ventricular ejection fraction (LVEF) \\<35% - as measured by radionuclide ventriculography (RNVG)\n* Patients with CHF secondary to ischaemic and non-ischaemic aetiology\n\nExclusion Criteria:\n\n* QRS duration \\>150ms (or QRS 120-150 with evidence of mechanical cardiac dysynchrony)\n* Magnetic resonance imaging (MRI) - incompatible metallic (ferrous) prosthesis\n* Primary valvular disease as a cause of CHF\n* Reversible causes of CHF\n* Acute myocarditis\n* Patients aged 18 or less\n* Patients having undergone revascularisation procedures within 6 months\n* Paroxysmal AF\n* Pregnancy\n* Expected cardiac transplantation within 6 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "16 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Derek T Connelly, MBChB", "affiliation": "Glasgow Royal Infirmary", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Glasgow Royal Infirmary", "city": "Glasgow", "state": "Scotland", "zip": "G31 2ER", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}]}, "referencesModule": {"references": [{"pmid": "21051458", "type": "DERIVED", "citation": "MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, Denvir M, Bhagra S, Small S, Martin W, McMurray JJ, Petrie MC. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart. 2011 May;97(9):740-7. doi: 10.1136/hrt.2010.207340. Epub 2010 Nov 4."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Medical Therapy", "description": "This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance."}, {"id": "FG001", "title": "Radiofrequency Ablation", "description": "Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Medical Therapy", "description": "This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance."}, {"id": "BG001", "title": "Radiofrequency Ablation", "description": "Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "41"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "64", "spread": "8"}, {"groupId": "BG001", "value": "62", "spread": "6.7"}, {"groupId": "BG002", "value": "63", "spread": "7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "32"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%", "description": "left ventricular ejection fraction (LVEF) is a measure of the % of blood ejected from the ventricle in one heart beat. It is a measure of cardiac function. We measured LVEF at baseline and at 6 months, to assess whether there had been a change in the patients cardiac function over time.", "populationDescription": "Number of patients analyzed is different from number of patients enrolled because some of the outcomes could not be measured in some patients ie the patient did not tolerate an mri or dropped out of the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of blood ejected in one beat", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "Medical Therapy", "description": "This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance."}, {"id": "OG001", "title": "Radiofrequency Ablation", "description": "Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.8", "spread": "6.8"}, {"groupId": "OG001", "value": "4.5", "spread": "11.1"}]}]}]}, {"type": "SECONDARY", "title": "Plasma B-type Natriuretic Peptide (BNP)", "description": "venous blood taken to assess levels of the above peptide. High evels of the peptide are associated with adverse prognosis. Blood levels are taken at baseline and 6 months. The change over 6 months is assessed, thereore it is possible to have a negative number if the level falls.", "populationDescription": "Number of patients analyzed is different from number of patients enrolled because some of the outcomes could not be measured in some patients ie the patient did not tolerate a blood test or dropped out of the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "picograms per millilitre", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "Medical Therapy", "description": "This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance."}, {"id": "OG001", "title": "Radiofrequency Ablation", "description": "Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "85", "spread": "648", "lowerLimit": "-563", "upperLimit": "733"}, {"groupId": "OG001", "value": "-196", "spread": "1469", "lowerLimit": "-1665", "upperLimit": "1273"}]}]}]}, {"type": "PRIMARY", "title": "Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)", "description": "Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)in %", "populationDescription": "Number of patients analyzed is different from number of patients enrolled because some of the outcomes could not be measured in some patients ie the patient did not tolerate an mri or dropped out of the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of blood ejected in one beat", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Medical Therapy", "description": "This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance."}, {"id": "OG001", "title": "Radiofrequency Ablation", "description": "Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "43", "spread": "10", "lowerLimit": "33", "upperLimit": "53"}, {"groupId": "OG001", "value": "36", "spread": "12", "lowerLimit": "24", "upperLimit": "48"}]}]}]}, {"type": "PRIMARY", "title": "Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months", "description": "Left Ventricular Ejection Fraction as measured by Magnetic Resonance Imaging (MRI)at 6 months", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of blood ejected in one beat", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Medical Therapy", "description": "This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance."}, {"id": "OG001", "title": "Radiofrequency Ablation", "description": "Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "46", "spread": "7", "lowerLimit": "39", "upperLimit": "53"}, {"groupId": "OG001", "value": "41", "spread": "11", "lowerLimit": "30", "upperLimit": "52"}]}]}]}, {"type": "SECONDARY", "title": "Plasma B-type Natriuretic Peptide (BNP) at Baseline", "description": "Plasma B-type Natriuretic Peptide (BNP) measured at basline", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "picograms per millilitre", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Medical Therapy", "description": "This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance."}, {"id": "OG001", "title": "Radiofrequency Ablation", "description": "Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1846", "spread": "1687", "lowerLimit": "159", "upperLimit": "3533"}, {"groupId": "OG001", "value": "2550", "spread": "2150", "lowerLimit": "400", "upperLimit": "4700"}]}]}]}, {"type": "SECONDARY", "title": "Plasma B-type Natriuretic Peptide (BNP) at 6 Months", "description": "Plasma B-type Natriuretic Peptide (BNP)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "picograms per millilitre", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Medical Therapy", "description": "This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance."}, {"id": "OG001", "title": "Radiofrequency Ablation", "description": "Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1931", "spread": "1671", "lowerLimit": "260", "upperLimit": "3608"}, {"groupId": "OG001", "value": "2354", "spread": "2632", "lowerLimit": "-278", "upperLimit": "4986"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Medical Therapy", "description": "This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance.", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 0, "otherNumAtRisk": 19}, {"id": "EG001", "title": "Radiofrequency Ablation", "description": "Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines.", "seriousNumAffected": 4, "seriousNumAtRisk": 22, "otherNumAffected": 0, "otherNumAtRisk": 22}], "seriousEvents": [{"term": "Stroke", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 22}]}, {"term": "Cardiac tamponade", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 22}]}, {"term": "heart failure hospitalisation", "organSystem": "Cardiac disorders", "notes": "within 1 week of the procedure", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 22}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Michael MacDonald", "organization": "NHS", "email": "michael.macdonald@nhs.net", "phone": "01412112000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-27"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000001281", "term": "Atrial Fibrillation"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000001145", "term": "Arrhythmias, Cardiac"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M4586", "name": "Atrial Fibrillation", "asFound": "Atrial Fibrillation", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M4453", "name": "Arrhythmias, Cardiac", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008790", "term": "Metoprolol"}, {"id": "D000077261", "term": "Carvedilol"}, {"id": "D000017257", "term": "Ramipril"}, {"id": "D000004656", "term": "Enalapril"}, {"id": "D000017706", "term": "Lisinopril"}, {"id": "D000017298", "term": "Bisoprolol"}, {"id": "D000020913", "term": "Perindopril"}, {"id": "D000002216", "term": "Captopril"}, {"id": "D000013148", "term": "Spironolactone"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000000451", "term": "Mineralocorticoid Receptor Antagonists"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}], "ancestors": [{"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000013565", "term": "Sympatholytics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000058671", "term": "Adrenergic beta-1 Receptor Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000062865", "term": "Diuretics, Potassium Sparing"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000002316", "term": "Cardiotonic Agents"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "Short-term", "relevance": "HIGH"}, {"id": "M15943", "name": "Spironolactone", "asFound": "Optimization", "relevance": "HIGH"}, {"id": "M5476", "name": "Captopril", "asFound": "Esophageal Squamous Cell Carcinoma", "relevance": "HIGH"}, {"id": "M7265", "name": "Digoxin", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M19924", "name": "Lisinopril", "asFound": "Aripiprazole", "relevance": "HIGH"}, {"id": "M11762", "name": "Metoprolol", "asFound": "Does not", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "asFound": "Parental", "relevance": "HIGH"}, {"id": "M22648", "name": "Perindopril", "asFound": "Nasopharyngeal Carcinoma", "relevance": "HIGH"}, {"id": "M19553", "name": "Ramipril", "asFound": "Keep", "relevance": "HIGH"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "asFound": "Ga-PSMA-", "relevance": "HIGH"}, {"id": "M19589", "name": "Bisoprolol", "asFound": "700", "relevance": "HIGH"}, {"id": "M7822", "name": "Enalapril", "asFound": "Patient Reported Outcomes", "relevance": "HIGH"}, {"id": "M18330", "name": "Enalaprilat", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3797", "name": "Mineralocorticoid Receptor Antagonists", "asFound": "Term pregnancy", "relevance": "HIGH"}, {"id": "M11871", "name": "Mineralocorticoids", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M16344", "name": "Sympatholytics", "relevance": "LOW"}, {"id": "M29197", "name": "Adrenergic beta-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M5572", "name": "Cardiotonic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}